ResMed (ASX: RMD) – 12-Month Investment Thesis (August 2026) Rating: BUY (close to Strong Buy if shares remain around current levels) 12-month Target Price: A$38–41 Estimated Upside: ~20–30% (depending on current share price) Confidence: High Investment Summary ResMed is one of the highest-quality healthcare companies listed on the ASX. Despite investor concerns around obesity drugs (GLP-1 medications such as Zepbound and Wegovy), the company’s operating performance has remained exceptionally strong.Read more